Disitamab vedotin combined with pyrotinib as salvage treatment in Her-2-amplified treatment refractory metastatic colorectal cancer: a case report
This case study suggests that the anti-Her-2 regimen involving Disitamab Vedotin and Pyrotinib may offer a potential salvage treatment option for patients with Her-2-amplified mCRC patients. However, further validation in larger cohorts is necessary in future studies.
Authors
- Qinhong Zheng
- Jian Wang (ORCID: https://orcid.org/0000-0002-9482-5227)
- Jianxin Chen (ORCID: https://orcid.org/0000-0002-0831-5934)
Institutions
- Zhejiang Chinese Medical University (CN)
- Wenzhou Medical University (CN)
- Quzhou City People's Hospital (CN)
- Quzhou University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-02-20
- DOI
- https://doi.org/10.3389/fphar.2025.1431422
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05